Correlation of An Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy

Correlation of An Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy

Background: Dosimetry can tailor prostate-specific membrane-antigen-targeted radioligand therapy (PSMA-RLT) for metastatic castration-resistant prostate cancer (mCRPC). However, whole-body tumor dosimetry is challenging in patients with a high tumor burden. We evaluate a simplified index-lesion-base...

Full description

Bibliographic Details
Main Authors: Friederike Völter, Lena Mittlmeier, Astrid Gosewisch, Julia Brosch-Lenz, Franz Josef Gildehaus, Mathias Johannes Zacherl, Leonie Beyer, Christian G. Stief, Adrien Holzgreve, Johannes Rübenthaler, Clemens C. Cyran, Guido Böning, Peter Bartenstein, Andrei Todica, Harun Ilhan
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Diagnostics
Subjects:
radioligand therapy
<sup>177</sup>Lu-PSMA
dosimetry
SPECT
mCRPC
Online Access:https://www.mdpi.com/2075-4418/11/3/428

Internet

https://www.mdpi.com/2075-4418/11/3/428

Similar Items